Copyright Reports & Markets. All rights reserved.

Global Patient-derived Xenograft (PDX) Models Market 2024 by Company, Regions, Type and Application, Forecast to 2030

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of Patient-derived Xenograft (PDX) Models by Type
    • 1.3.1 Overview: Global Patient-derived Xenograft (PDX) Models Market Size by Type: 2019 Versus 2023 Versus 2030
    • 1.3.2 Global Patient-derived Xenograft (PDX) Models Consumption Value Market Share by Type in 2023
    • 1.3.3 Mouse Model
    • 1.3.4 Rat Model
  • 1.4 Global Patient-derived Xenograft (PDX) Models Market by Application
    • 1.4.1 Overview: Global Patient-derived Xenograft (PDX) Models Market Size by Application: 2019 Versus 2023 Versus 2030
    • 1.4.2 Preclinical Drug development
    • 1.4.3 Biomarker Analysis
  • 1.5 Global Patient-derived Xenograft (PDX) Models Market Size & Forecast
  • 1.6 Global Patient-derived Xenograft (PDX) Models Market Size and Forecast by Region
    • 1.6.1 Global Patient-derived Xenograft (PDX) Models Market Size by Region: 2019 VS 2023 VS 2030
    • 1.6.2 Global Patient-derived Xenograft (PDX) Models Market Size by Region, (2019-2030)
    • 1.6.3 North America Patient-derived Xenograft (PDX) Models Market Size and Prospect (2019-2030)
    • 1.6.4 Europe Patient-derived Xenograft (PDX) Models Market Size and Prospect (2019-2030)
    • 1.6.5 Asia-Pacific Patient-derived Xenograft (PDX) Models Market Size and Prospect (2019-2030)
    • 1.6.6 South America Patient-derived Xenograft (PDX) Models Market Size and Prospect (2019-2030)
    • 1.6.7 Middle East & Africa Patient-derived Xenograft (PDX) Models Market Size and Prospect (2019-2030)

2 Company Profiles

  • 2.1 Crown Bioscience
    • 2.1.1 Crown Bioscience Details
    • 2.1.2 Crown Bioscience Major Business
    • 2.1.3 Crown Bioscience Patient-derived Xenograft (PDX) Models Product and Solutions
    • 2.1.4 Crown Bioscience Patient-derived Xenograft (PDX) Models Revenue, Gross Margin and Market Share (2019-2024)
    • 2.1.5 Crown Bioscience Recent Developments and Future Plans
  • 2.2 Champions Oncology
    • 2.2.1 Champions Oncology Details
    • 2.2.2 Champions Oncology Major Business
    • 2.2.3 Champions Oncology Patient-derived Xenograft (PDX) Models Product and Solutions
    • 2.2.4 Champions Oncology Patient-derived Xenograft (PDX) Models Revenue, Gross Margin and Market Share (2019-2024)
    • 2.2.5 Champions Oncology Recent Developments and Future Plans
  • 2.3 Wuxi Apptec
    • 2.3.1 Wuxi Apptec Details
    • 2.3.2 Wuxi Apptec Major Business
    • 2.3.3 Wuxi Apptec Patient-derived Xenograft (PDX) Models Product and Solutions
    • 2.3.4 Wuxi Apptec Patient-derived Xenograft (PDX) Models Revenue, Gross Margin and Market Share (2019-2024)
    • 2.3.5 Wuxi Apptec Recent Developments and Future Plans
  • 2.4 The Jackson Laboratory
    • 2.4.1 The Jackson Laboratory Details
    • 2.4.2 The Jackson Laboratory Major Business
    • 2.4.3 The Jackson Laboratory Patient-derived Xenograft (PDX) Models Product and Solutions
    • 2.4.4 The Jackson Laboratory Patient-derived Xenograft (PDX) Models Revenue, Gross Margin and Market Share (2019-2024)
    • 2.4.5 The Jackson Laboratory Recent Developments and Future Plans
  • 2.5 EPO Berlin-Buch
    • 2.5.1 EPO Berlin-Buch Details
    • 2.5.2 EPO Berlin-Buch Major Business
    • 2.5.3 EPO Berlin-Buch Patient-derived Xenograft (PDX) Models Product and Solutions
    • 2.5.4 EPO Berlin-Buch Patient-derived Xenograft (PDX) Models Revenue, Gross Margin and Market Share (2019-2024)
    • 2.5.5 EPO Berlin-Buch Recent Developments and Future Plans
  • 2.6 Oncodesign
    • 2.6.1 Oncodesign Details
    • 2.6.2 Oncodesign Major Business
    • 2.6.3 Oncodesign Patient-derived Xenograft (PDX) Models Product and Solutions
    • 2.6.4 Oncodesign Patient-derived Xenograft (PDX) Models Revenue, Gross Margin and Market Share (2019-2024)
    • 2.6.5 Oncodesign Recent Developments and Future Plans
  • 2.7 Xentech
    • 2.7.1 Xentech Details
    • 2.7.2 Xentech Major Business
    • 2.7.3 Xentech Patient-derived Xenograft (PDX) Models Product and Solutions
    • 2.7.4 Xentech Patient-derived Xenograft (PDX) Models Revenue, Gross Margin and Market Share (2019-2024)
    • 2.7.5 Xentech Recent Developments and Future Plans
  • 2.8 Envigo
    • 2.8.1 Envigo Details
    • 2.8.2 Envigo Major Business
    • 2.8.3 Envigo Patient-derived Xenograft (PDX) Models Product and Solutions
    • 2.8.4 Envigo Patient-derived Xenograft (PDX) Models Revenue, Gross Margin and Market Share (2019-2024)
    • 2.8.5 Envigo Recent Developments and Future Plans
  • 2.9 Charles River Laboratories
    • 2.9.1 Charles River Laboratories Details
    • 2.9.2 Charles River Laboratories Major Business
    • 2.9.3 Charles River Laboratories Patient-derived Xenograft (PDX) Models Product and Solutions
    • 2.9.4 Charles River Laboratories Patient-derived Xenograft (PDX) Models Revenue, Gross Margin and Market Share (2019-2024)
    • 2.9.5 Charles River Laboratories Recent Developments and Future Plans
  • 2.10 Pharmatest Services
    • 2.10.1 Pharmatest Services Details
    • 2.10.2 Pharmatest Services Major Business
    • 2.10.3 Pharmatest Services Patient-derived Xenograft (PDX) Models Product and Solutions
    • 2.10.4 Pharmatest Services Patient-derived Xenograft (PDX) Models Revenue, Gross Margin and Market Share (2019-2024)
    • 2.10.5 Pharmatest Services Recent Developments and Future Plans
  • 2.11 Urosphere
    • 2.11.1 Urosphere Details
    • 2.11.2 Urosphere Major Business
    • 2.11.3 Urosphere Patient-derived Xenograft (PDX) Models Product and Solutions
    • 2.11.4 Urosphere Patient-derived Xenograft (PDX) Models Revenue, Gross Margin and Market Share (2019-2024)
    • 2.11.5 Urosphere Recent Developments and Future Plans
  • 2.12 MEDICILON
    • 2.12.1 MEDICILON Details
    • 2.12.2 MEDICILON Major Business
    • 2.12.3 MEDICILON Patient-derived Xenograft (PDX) Models Product and Solutions
    • 2.12.4 MEDICILON Patient-derived Xenograft (PDX) Models Revenue, Gross Margin and Market Share (2019-2024)
    • 2.12.5 MEDICILON Recent Developments and Future Plans
  • 2.13 Horizon Discovery
    • 2.13.1 Horizon Discovery Details
    • 2.13.2 Horizon Discovery Major Business
    • 2.13.3 Horizon Discovery Patient-derived Xenograft (PDX) Models Product and Solutions
    • 2.13.4 Horizon Discovery Patient-derived Xenograft (PDX) Models Revenue, Gross Margin and Market Share (2019-2024)
    • 2.13.5 Horizon Discovery Recent Developments and Future Plans
  • 2.14 Shanghai Model Organisms Center
    • 2.14.1 Shanghai Model Organisms Center Details
    • 2.14.2 Shanghai Model Organisms Center Major Business
    • 2.14.3 Shanghai Model Organisms Center Patient-derived Xenograft (PDX) Models Product and Solutions
    • 2.14.4 Shanghai Model Organisms Center Patient-derived Xenograft (PDX) Models Revenue, Gross Margin and Market Share (2019-2024)
    • 2.14.5 Shanghai Model Organisms Center Recent Developments and Future Plans
  • 2.15 GemPharmatech
    • 2.15.1 GemPharmatech Details
    • 2.15.2 GemPharmatech Major Business
    • 2.15.3 GemPharmatech Patient-derived Xenograft (PDX) Models Product and Solutions
    • 2.15.4 GemPharmatech Patient-derived Xenograft (PDX) Models Revenue, Gross Margin and Market Share (2019-2024)
    • 2.15.5 GemPharmatech Recent Developments and Future Plans
  • 2.16 LIDE Biotech
    • 2.16.1 LIDE Biotech Details
    • 2.16.2 LIDE Biotech Major Business
    • 2.16.3 LIDE Biotech Patient-derived Xenograft (PDX) Models Product and Solutions
    • 2.16.4 LIDE Biotech Patient-derived Xenograft (PDX) Models Revenue, Gross Margin and Market Share (2019-2024)
    • 2.16.5 LIDE Biotech Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Patient-derived Xenograft (PDX) Models Revenue and Share by Players (2019-2024)
  • 3.2 Market Share Analysis (2023)
    • 3.2.1 Market Share of Patient-derived Xenograft (PDX) Models by Company Revenue
    • 3.2.2 Top 3 Patient-derived Xenograft (PDX) Models Players Market Share in 2023
    • 3.2.3 Top 6 Patient-derived Xenograft (PDX) Models Players Market Share in 2023
  • 3.3 Patient-derived Xenograft (PDX) Models Market: Overall Company Footprint Analysis
    • 3.3.1 Patient-derived Xenograft (PDX) Models Market: Region Footprint
    • 3.3.2 Patient-derived Xenograft (PDX) Models Market: Company Product Type Footprint
    • 3.3.3 Patient-derived Xenograft (PDX) Models Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global Patient-derived Xenograft (PDX) Models Consumption Value and Market Share by Type (2019-2024)
  • 4.2 Global Patient-derived Xenograft (PDX) Models Market Forecast by Type (2025-2030)

5 Market Size Segment by Application

  • 5.1 Global Patient-derived Xenograft (PDX) Models Consumption Value Market Share by Application (2019-2024)
  • 5.2 Global Patient-derived Xenograft (PDX) Models Market Forecast by Application (2025-2030)

6 North America

  • 6.1 North America Patient-derived Xenograft (PDX) Models Consumption Value by Type (2019-2030)
  • 6.2 North America Patient-derived Xenograft (PDX) Models Market Size by Application (2019-2030)
  • 6.3 North America Patient-derived Xenograft (PDX) Models Market Size by Country
    • 6.3.1 North America Patient-derived Xenograft (PDX) Models Consumption Value by Country (2019-2030)
    • 6.3.2 United States Patient-derived Xenograft (PDX) Models Market Size and Forecast (2019-2030)
    • 6.3.3 Canada Patient-derived Xenograft (PDX) Models Market Size and Forecast (2019-2030)
    • 6.3.4 Mexico Patient-derived Xenograft (PDX) Models Market Size and Forecast (2019-2030)

7 Europe

  • 7.1 Europe Patient-derived Xenograft (PDX) Models Consumption Value by Type (2019-2030)
  • 7.2 Europe Patient-derived Xenograft (PDX) Models Consumption Value by Application (2019-2030)
  • 7.3 Europe Patient-derived Xenograft (PDX) Models Market Size by Country
    • 7.3.1 Europe Patient-derived Xenograft (PDX) Models Consumption Value by Country (2019-2030)
    • 7.3.2 Germany Patient-derived Xenograft (PDX) Models Market Size and Forecast (2019-2030)
    • 7.3.3 France Patient-derived Xenograft (PDX) Models Market Size and Forecast (2019-2030)
    • 7.3.4 United Kingdom Patient-derived Xenograft (PDX) Models Market Size and Forecast (2019-2030)
    • 7.3.5 Russia Patient-derived Xenograft (PDX) Models Market Size and Forecast (2019-2030)
    • 7.3.6 Italy Patient-derived Xenograft (PDX) Models Market Size and Forecast (2019-2030)

8 Asia-Pacific

  • 8.1 Asia-Pacific Patient-derived Xenograft (PDX) Models Consumption Value by Type (2019-2030)
  • 8.2 Asia-Pacific Patient-derived Xenograft (PDX) Models Consumption Value by Application (2019-2030)
  • 8.3 Asia-Pacific Patient-derived Xenograft (PDX) Models Market Size by Region
    • 8.3.1 Asia-Pacific Patient-derived Xenograft (PDX) Models Consumption Value by Region (2019-2030)
    • 8.3.2 China Patient-derived Xenograft (PDX) Models Market Size and Forecast (2019-2030)
    • 8.3.3 Japan Patient-derived Xenograft (PDX) Models Market Size and Forecast (2019-2030)
    • 8.3.4 South Korea Patient-derived Xenograft (PDX) Models Market Size and Forecast (2019-2030)
    • 8.3.5 India Patient-derived Xenograft (PDX) Models Market Size and Forecast (2019-2030)
    • 8.3.6 Southeast Asia Patient-derived Xenograft (PDX) Models Market Size and Forecast (2019-2030)
    • 8.3.7 Australia Patient-derived Xenograft (PDX) Models Market Size and Forecast (2019-2030)

9 South America

  • 9.1 South America Patient-derived Xenograft (PDX) Models Consumption Value by Type (2019-2030)
  • 9.2 South America Patient-derived Xenograft (PDX) Models Consumption Value by Application (2019-2030)
  • 9.3 South America Patient-derived Xenograft (PDX) Models Market Size by Country
    • 9.3.1 South America Patient-derived Xenograft (PDX) Models Consumption Value by Country (2019-2030)
    • 9.3.2 Brazil Patient-derived Xenograft (PDX) Models Market Size and Forecast (2019-2030)
    • 9.3.3 Argentina Patient-derived Xenograft (PDX) Models Market Size and Forecast (2019-2030)

10 Middle East & Africa

  • 10.1 Middle East & Africa Patient-derived Xenograft (PDX) Models Consumption Value by Type (2019-2030)
  • 10.2 Middle East & Africa Patient-derived Xenograft (PDX) Models Consumption Value by Application (2019-2030)
  • 10.3 Middle East & Africa Patient-derived Xenograft (PDX) Models Market Size by Country
    • 10.3.1 Middle East & Africa Patient-derived Xenograft (PDX) Models Consumption Value by Country (2019-2030)
    • 10.3.2 Turkey Patient-derived Xenograft (PDX) Models Market Size and Forecast (2019-2030)
    • 10.3.3 Saudi Arabia Patient-derived Xenograft (PDX) Models Market Size and Forecast (2019-2030)
    • 10.3.4 UAE Patient-derived Xenograft (PDX) Models Market Size and Forecast (2019-2030)

11 Market Dynamics

  • 11.1 Patient-derived Xenograft (PDX) Models Market Drivers
  • 11.2 Patient-derived Xenograft (PDX) Models Market Restraints
  • 11.3 Patient-derived Xenograft (PDX) Models Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

  • 12.1 Patient-derived Xenograft (PDX) Models Industry Chain
  • 12.2 Patient-derived Xenograft (PDX) Models Upstream Analysis
  • 12.3 Patient-derived Xenograft (PDX) Models Midstream Analysis
  • 12.4 Patient-derived Xenograft (PDX) Models Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Patient-derived Xenograft (PDX) Models market size was valued at US$ 370 million in 2023 and is forecast to a readjusted size of USD 645 million by 2030 with a CAGR of 8.3% during review period.
    Global top 5 manufacturers of patient-derived xenograft (PDX) models occupied for a share nearly 45 percent, key players are Crown Bioscience, Champions Oncology, Wuxi Apptec, EPO Berlin-Buch, and Oncodesign, etc. Geographically speaking, Asia Pacific holds the most of global market share, about 35%. North America holds about 30% of share, while Europe followed by nearly 20%. In terms of type, mouse model accounted for nearly 75%, and rat model accounted for a share of 25%,The application of patient-derived xenograft (PDX) models includes preclinical drug development and biomarker analysis. Preclinical drug development shares over 75%, while biomarker analysis shares about 20%.
    This report is a detailed and comprehensive analysis for global Patient-derived Xenograft (PDX) Models market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2024, are provided.
    Key Features:
    Global Patient-derived Xenograft (PDX) Models market size and forecasts, in consumption value ($ Million), 2019-2030
    Global Patient-derived Xenograft (PDX) Models market size and forecasts by region and country, in consumption value ($ Million), 2019-2030
    Global Patient-derived Xenograft (PDX) Models market size and forecasts, by Type and by Application, in consumption value ($ Million), 2019-2030
    Global Patient-derived Xenograft (PDX) Models market shares of main players, in revenue ($ Million), 2019-2024
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Patient-derived Xenograft (PDX) Models
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Patient-derived Xenograft (PDX) Models market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Crown Bioscience, Champions Oncology, Wuxi Apptec, The Jackson Laboratory, EPO Berlin-Buch, Oncodesign, Xentech, Envigo, Charles River Laboratories, Pharmatest Services, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market segmentation
    Patient-derived Xenograft (PDX) Models market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
    Market segmentation
    Patient-derived Xenograft (PDX) Models market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Mouse Model
    Rat Model
    Market segment by Application
    Preclinical Drug development
    Biomarker Analysis
    Market segment by players, this report covers
    Crown Bioscience
    Champions Oncology
    Wuxi Apptec
    The Jackson Laboratory
    EPO Berlin-Buch
    Oncodesign
    Xentech
    Envigo
    Charles River Laboratories
    Pharmatest Services
    Urosphere
    MEDICILON
    Horizon Discovery
    Shanghai Model Organisms Center
    GemPharmatech
    LIDE Biotech
    Market segment by regions, regional analysis covers
    North America (United States, Canada and Mexico)
    Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
    South America (Brazil, Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 13 chapters:
    Chapter 1, to describe Patient-derived Xenograft (PDX) Models product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top players of Patient-derived Xenograft (PDX) Models, with revenue, gross margin, and global market share of Patient-derived Xenograft (PDX) Models from 2019 to 2024.
    Chapter 3, the Patient-derived Xenograft (PDX) Models competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
    Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2019 to 2030.
    Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Patient-derived Xenograft (PDX) Models market forecast, by regions, by Type and by Application, with consumption value, from 2024 to 2030.
    Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
    Chapter 12, the key raw materials and key suppliers, and industry chain of Patient-derived Xenograft (PDX) Models.
    Chapter 13, to describe Patient-derived Xenograft (PDX) Models research findings and conclusion.

    Buy now